Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge
Microdosing Unveiled: Expert’s Take On The Practice’s Ups & Downs
(See Part 1: Exclusive Insights: How Tech Leaders Are Finding Balance Through Microdosing Psychedelics)
Exclusive Insights: How Tech Leaders Are Finding Balance Through Microdosing Psychedelics
Psychedelics are one of the buzziest topics in tech these days.
From Fast-Acting Hemp Extracts To Wiz Khalifa Mushroom Kits: Tracking Progressive Trends In Cannabis & Psychedelics
The world of cannabis and psychedelics is evolving at a rapid pace, with companies introducing groundbreaking products and expanding into new markets.
Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression
Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive Disorder (MDD.)
Peru’s Coca Leaf Will Be Used For Research Toward Treating ADHD, Learn The Details
Magdalena Biosciences, Jaguar Health (NASDAQ: JAGX) and Filament Health (OTCQB: FLHLF)
Enveric Biosciences Nabs U.S. Patent For Novel Psilocybin Derivatives, Details Here
The U.S. Patent and Trademark Office (USPTO) has issued a new patent granting IP rights for the novel composition of matter and methods of use on the psilocybin-based molecules series EVM301 to its developer, Enveric Biosciences (NASDAQ: ENVB).
Oregon’s Voter-Approved Drug Decriminalization Law Under Attack, Ballot Proposal Circulating
Two petitions are circulating in Oregon to overturn the 2020 voter-approved Measure 110 that decriminalized the simple possession of drugs.
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland’s Consumption Site & More
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next
Hope For Postpartum Depression: This Company To Launch Clinical Trial On Next-Gen Psychedelic
Clinical-stage biopharma company Reunion Neuroscience has received the FDA’s clearance on its Investigational New Drug (IND) application to begin a Phase 2 study of RE104, a novel serotonergic psychedelic compound aimed at treating postpartum depression (PPD.)